Consensus Relay Therapeutics, Inc.

Stocks

RLAY

US75943R1023

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:04:39 29/10/2026 +04			5-day change	1st Jan Change
19.93 ^USD	+1.22%		+9.16%	+136.64%

10-09	Relay Therapeutics Insider Sold Shares Worth $872,402, According to a Recent SEC Filing	MT
10-09	Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC Filing	MT

Evolution of the Average Target: Relay Therapeutics, Inc.

Evolution of the Target Price: Relay Therapeutics, Inc.

Changes in Analyst Recommendations: Relay Therapeutics, Inc.

6c6bec560b1cbf3420e960a458cc.u7WriHlRXy8yUgjFELj0P_0HAYE4X8aIMzin4Aj4-T4.6_Pv3AE0OAIGNUr9Itu1ErpFNPFUGIG_Z0vCzUyoj27J5uK8DTAKQ3QTQQ~a358933dc16c57f4bac37075b081f6ec

Analysts' recommendations: Relay Therapeutics, Inc.

07-16	Canaccord Genuity Initiates Relay Therapeutics at Buy With $29 Price Target	MT
04-28	Oppenheimer Adjusts Relay Therapeutics Price Target to $18 From $14, Maintains Outperform Rating	MT
01-26	Oppenheimer Upgrades Relay Therapeutics to Outperform From Market Perform, Price Target is $14	MT
11-07	Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025	CI
26/08/25	HC Wainwright Adjusts Price Target on Relay Therapeutics to $14 From $16, Maintains Buy Rating	MT
17/04/25	Wells Fargo Initiates Relay Therapeutics at Equalweight With $4 Price Target	MT
10/09/24	Jefferies Upgrades Relay Therapeutics to Buy From Hold, Price Target is $16	MT
10/09/24	Oppenheimer Downgrades Relay Therapeutics to Perform From Outperform, Price Target is $24	MT
09/09/24	Barclays Raises Price Target on Relay Therapeutics to $17 From $14, Keeps Overweight Rating	MT
07/08/24	Oppenheimer Trims Relay Therapeutics Price Target to $24 From $25, Maintains Outperform Rating	MT
18/07/24	JMP Securities Cuts Price Target on Relay Therapeutics to $21 From $24, Maintains Market Outperform Rating	MT
17/07/24	HC Wainwright Adjusts Price Target on Relay Therapeutics to $18 From $20, Maintains Buy Rating	MT
10/05/24	Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target	MT
06/05/24	Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating	MT
11/12/23	HC Wainwright Adjusts Price Target on Relay Therapeutics to $17 From $19, Keeps Buy Rating	MT
08/11/23	HC Wainwright Lowers Price Target on Relay Therapeutics to $19 From $33, Maintains Buy Rating	MT
17/08/23	HC Wainwright Adjusts Price Target on Relay Therapeutics to $30 From $32, Keeps Buy Rating	MT
26/04/23	Berenberg Bank Adjusts Relay Therapeutics Price Target to $28 From $40, Maintains Buy Rating	MT
20/04/23	Jefferies Upgrades Relay Therapeutics to Hold From Underperform, Adjusts Price Target to $12.50 From $16	MT
20/04/23	Stifel Adjusts Price Target on Relay Therapeutics to $34 From $38, Maintains Buy Rating	MT
19/04/23	JPMorgan Adjusts Price Target on Relay Therapeutics to $29 From $42, Keeps Overweight Rating	MT
19/04/23	Raymond James Upgrade Relay Therapeutics to Strong Buy Rating From Outperform, Price Target is $29	MT
19/04/23	Barclays Cuts Price Target on Relay Therapeutics to $15 From $23, Keeps Equalweight Rating	MT
13/04/23	Raymond James Initiates Relay Therapeutics at Outperform With $29 Price Target	MT
05/04/23	JPMorgan Adjusts Price Target on Relay Therapeutics to $42 From $45, Maintains Overweight Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	RELAY THERAPEUTICS, INC.					+40.09%
	WUXI APPTEC CO., LTD.					+41.72%
	ARGENX SE					+26.36%
	LONZA GROUP AG					+10.61%
	IQVIA HOLDINGS INC.					+10.61%
	BEONE MEDICINES AG					+16.9%
	REVOLUTION MEDICINES, INC.					+37.16%
	CELLTRION, INC.					+42.61%
	GENMAB A/S					-17.48%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.19%
	Average					+23.88%
	Weighted average by Cap.					+22.90%